Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

179 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Hadziyannis SJ, et al. Ann Intern Med. 2004 Mar 2;140(5):346-55. doi: 10.7326/0003-4819-140-5-200403020-00010. Ann Intern Med. 2004. PMID: 14996676 Clinical Trial.
Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin.
McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, Ling MH, Garaud JJ, Albrecht JK, Patel K, Dienstag JL, Morgan T; International Hepatitis Interventional Therapy Group. McHutchison JG, et al. Hepatology. 2002 Mar;35(3):688-93. doi: 10.1053/jhep.2002.31870. Hepatology. 2002. PMID: 11870385
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, McNally J, Brainard DM, Han L, Doehle B, McHutchison JG, Morgan T, Chung RT, Tran TT. Everson GT, et al. Ann Intern Med. 2015 Dec 1;163(11):818-26. doi: 10.7326/M15-1000. Epub 2015 Nov 10. Ann Intern Med. 2015. PMID: 26551051 Clinical Trial.
Predictors of Early Discontinuation of Pegylated Interferon for Reasons Other Than Lack of Efficacy in United States Veterans With Chronic Hepatitis C.
LaFleur J, Hoop R, Korner E, DuVall S, Morgan T, Pandya P, Han J, Knippenberg K, Nelson RE. LaFleur J, et al. Gastroenterol Nurs. 2015 Nov-Dec;38(6):417-28. doi: 10.1097/SGA.0000000000000214. Gastroenterol Nurs. 2015. PMID: 26626031
The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial.
Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA, Kulig CC, Curto TM, Wright EC; Halt-C Trial Group. Everson GT, et al. Aliment Pharmacol Ther. 2008 May;27(9):798-809. doi: 10.1111/j.1365-2036.2008.03639.x. Epub 2008 Feb 7. Aliment Pharmacol Ther. 2008. PMID: 18266997
Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial.
Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Desanto JL, Curto TM, Wright EC; HALT-C Trial Group. Everson GT, et al. Aliment Pharmacol Ther. 2009 Mar 1;29(5):589-601. doi: 10.1111/j.1365-2036.2008.03908.x. Epub 2008 Dec 1. Aliment Pharmacol Ther. 2009. PMID: 19053983 Free PMC article. Clinical Trial.
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.
Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Häussinger D, Shiffman ML, Hadziyannis SJ, Schmidt WN, Jacobson IM, Bárcena R, Schiff ER, Shaikh OS, Bacon B, Marcellin P, Deng W, Esteban-Mur R, Poynard T, Pedicone LD, Brass CA, Albrecht JK, Gordon SC. Manns MP, et al. J Viral Hepat. 2013 Aug;20(8):524-9. doi: 10.1111/jvh.12074. Epub 2013 Mar 3. J Viral Hepat. 2013. PMID: 23808990 Clinical Trial.
Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C.
Snow KK, Bonkovsky HL, Fontana RJ, Kim HY, Sterling RK, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG; HALT-C Trial Group. Snow KK, et al. Aliment Pharmacol Ther. 2010 Apr;31(7):719-34. doi: 10.1111/j.1365-2036.2010.04235.x. Epub 2010 Jan 12. Aliment Pharmacol Ther. 2010. PMID: 20070284 Free PMC article. Clinical Trial.
Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.
McHutchison JG, Shad JA, Gordon SC, Morgan TR, Ling MH, Garaud JJ, Albrecht JK, Dienstag JL. McHutchison JG, et al. J Viral Hepat. 2001 Nov;8(6):414-20. doi: 10.1046/j.1365-2893.2001.00312.x. J Viral Hepat. 2001. PMID: 11703572 Clinical Trial.
Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.
Bräu N, Bini EJ, Currie S, Shen H, Schmidt WN, King PD, Ho SB, Cheung RC, Hu KQ, Anand BS, Simon FR, Aytaman A, Johnson DP, Awad JA, Ahmad J, Mendenhall CL, Pedrosa MC, Moseley RH, Hagedorn CH, Waters B, Chang KM, Morgan TR, Rossi SJ, Jeffers LJ, Wright TL; VA-HCV-001 Study Group. Bräu N, et al. J Viral Hepat. 2006 Apr;13(4):242-9. doi: 10.1111/j.1365-2893.2005.00682.x. J Viral Hepat. 2006. PMID: 16611190 Clinical Trial.
179 results
Jump to page
Feedback